Holen Sie sich die Stockscreener-App
29.76
4.03%
-1.25
Handel nachbörslich:
30.05
0.29
+0.97%
Schlusskurs vom Vortag:
$31.01
Offen:
$28.585
24-Stunden-Volumen:
58.72M
Relative Volume:
1.61
Marktkapitalisierung:
$6.78B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$128.37M
KGV:
57.00
EPS:
0.5221
Netto-Cashflow:
$57.42M
1W Leistung:
+39.33%
1M Leistung:
+35.15%
6M Leistung:
-39.71%
1J Leistung:
+15.17%
1-Tages-Spanne:
$27.85
$30.87
1-Wochen-Bereich:
$21.28
$31.86
52-Wochen-Spanne:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
29.76 | 7.07B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
17.06 | 55.44B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
118.18 | 51.61B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.53 | 43.06B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.29 | 37.28B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
573.46 | 25.13B | 3.18B | 1.33B | 1.04B | 27.90 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Hochstufung | Citigroup | Sell → Neutral |
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Why Is Hims & Hers Health Stock Falling Tuesday?Hims & Hers Health (NYSE:HIMS) - Benzinga
Did Amazon Just Wreck All of Hims & Hers Upside Potential? - Yahoo Finance
HIMS Stock On Track To Fall For The First Time In Seven Sessions – Why Is Amazon’s GLP-1 Program In The Spotlight? - Stocktwits
Hims & Hers Builds Scalable Data-Driven Personalized Care Platform - Yahoo! Finance Canada
(HIMS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Hims & Hers Health stock falls after Amazon launches GLP-1 program - Investing.com Canada
Hims & Hers (HIMS) Stock Up 49% in Five Days on FDA Peptide Review and Novo Nordisk Deal - CoinCentral
3 Stocks That May Be Trading Below Their Estimated Intrinsic Value - simplywall.st
Hims & Hers Health Shares Surge 48 Percent Ahead of Earnings Report - HarianBasis.co
Significant Bullish Momentum for Hims and Hers Health (HIMS) - GuruFocus
Hims & Hers Health Inc (HIMS) Stock Up 7.6% and Still Undervalued -- GF Score: 81/100 - GuruFocus
Hims & Hers CFO Okupe Oluyemi sells $1.46 million in company stock - Investing.com
Hims & Hers (HIMS) CFO sells 54,927 shares under 10b5-1 plan - Stock Titan
HIMS (HIMS) insider sale notice: 4,651 and 4,812 Class A shares listed - Stock Titan
Hims & Hers Surges Ahead of Earnings as Omnicell Lags in Healthcare Tech Shakeout - TechStock²
Hims & Hers Health stock price forecast: $28.50–$31.80 range as HIMS climbs 4.68% - Traders Union
Why Hims & Hers Health Stock Is Surging Monday - Benzinga
Hims & Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal - AOL.com
Cheap Weight-Loss Drugs Are Great — When They're Legal - Bloomberg.com
Novo Deal, Eucalyptus Acquisition, FDA Peptides: Three Catalysts Reshaping Hims & Hers in 2026 - TIKR.com
Hims shares rise as US moves to ease peptide regulations - Global Cosmetics News
Hims & Hers powers patient-provider connectivity via digital platforms - MSN
Hims & Hers (HIMS) Jumps 48% Ahead of Earnings - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Hims & Hers Health, Inc. (HIMS) And Encourages Stockholders to Reach Out - ACCESS Newswire
2026-04-19 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Hims & Hers Health, Inc. (HIMS) And Encourages Stockholders to Reach Out | NYSE:HIMS | Press Release - Stockhouse
Hims & Hers May Have Just Rewritten Its Entire Business Model! - Smartkarma
Healthcare Technology Q4 2025 Report: Sector Revenue Beat & Stock SurgeNews and Statistics - IndexBox
Hims & Hers expands personalized digital healthcare platform - MSN
Hims & Hers Health Inc (HIMS) Stock Price, Quote, News & History - Benzinga
Weekly Market Update: Stocks Gain 4.62% to Hit New All-Time High as Tech Rises, Energy Falls - Morningstar
Hims & Hers Health, Inc. (NYSE:HIMS) Sees Large Drop in Short Interest - MarketBeat
HIMS Stock | Hims & Hers Health Price, Quote, News & Analysis - TipRanks
HIMS Receives Upgrade Amid Positive Regulatory Outlook - GuruFocus
7 Health Care Stocks Whale Activity In Today's Session - Benzinga
Is It Time To Reassess Hims & Hers Health (HIMS) After The Recent Share Price Surge - Yahoo Finance
SA analyst upgrades/downgrades: NVDA, VZ, MRVL, HIMS - Seeking Alpha
Hims & Hers Stock Surges 13% on FDA Peptide Review Optimism and Telehealth Momentum - International Business Times Australia
+7.34% for Hims & Hers Health stock as FDA eyes peptide drug policy change - Traders Union
What's Going On With Hims & Hers Shares - Benzinga
Here’s How Cedar Grove Capital Management Benefitted from Its Short Position in Hims & Hers Health (HIMS) - Yahoo Finance
Hims & Hers stock rises 14% as FDA schedules peptide compounding review - Yahoo Finance
Hims & Hers Health (HIMS) Soars 11.1%: Is Further Upside Left in the Stock? - Yahoo Finance
Hims Hers Health Surprise Signals New Healthcare Momentum Shift Ahead - Kalkine Media
Investor relations - HIMS Investor Relations
HIMS Stock's Rally May Have Plenty Of Room Left: FDA Opens Door To Testosterone Therapy - Stocktwits
HIMS Stock Closes Another Day In The Green — But Retail Sees More Upside - Stocktwits
Why Is HIMS Stock Surging More Than 11% After-Hours Today? - Stocktwits
Q4 Earnings Outperformers: Hims & Hers Health (NYSE:HIMS) And The Rest Of The Healthcare Technology Stocks - Yahoo Finance
Hims & Hers to partner with Novo Nordisk and stop selling compounded GLP-1s - AOL.com
HIMS Stock Rises 7% on Potential FDA Regulatory Changes - GuruFocus
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Hims Hers Health Inc-Aktie (HIMS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Okupe Oluyemi | Chief Financial Officer |
Apr 16 '26 |
Sale |
25.90 |
36,922 |
956,147 |
281,867 |
| Okupe Oluyemi | Chief Financial Officer |
Apr 17 '26 |
Sale |
27.83 |
18,005 |
501,158 |
270,046 |
2.44%
1.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):